Molbio Diagnostics made its stock market debut at ₹980, a premium of over 21 per cent to its issue price of ₹807, after raising around ₹940 crore through its IPO. The company plans to deploy the fresh capital towards a new R&D facility and manufacturing automation, while expanding its presence across developed markets including the US and Europe. Business Today TV speaks to Sriram Natarajan, CEO, Molbio Diagnostics, on the company's post-IPO growth plans, Truenat's expansion into new disease areas, international opportunities, digital pathology, veterinary diagnostics and the road ahead.
Dubai commercial property deals nearly triple to AED 15.8 bn as prices surge 85%
Su-30MKI, warships and missiles: India adds 405 items to defence indigenisation list
Your Favourite Whisky May Taste Different Now | Why Diageo Is Changing Whisky & Rum Recipes | FSSAI
BSE shareholders in a fix: Two downgrades in two days; where is the stock headed?
India-U.S. Trade Hits $240 Billion | Sergio Gor Eyes $500 Billion By 2030BSE shareholders in a fix: Two downgrades in two days; where is the stock headed?
Buy Hind Copper shares? Target as global peers trade at 10-year valuation multiple peaks
Tata Steel, JSW Steel, Jindal Steel share price targets: 3 metal stocks to buy 
NSE IPO update: Listing-bound exchange pegs valuation? Expected price band, IPO timeline & more
Sterlite Tech, KEI, Polycab, Havells: Targets for cables & wires stocks, top 2 picksYour Favourite Whisky May Taste Different Now | Why Diageo Is Changing Whisky & Rum Recipes | FSSAI
Mahindra Eyes Bigger Share Of India’s Truck Market, Targets ₹12,500 Crore Business By FY31
India’s Electronics Manufacturing Grows 7X To ₹13 Lakh Crore, Says Ashwini Vaishnaw
Vijay’s First 100 Days: Tamil Nadu Govt Faces Praise, Questions At India Today Roundtable
K Annamalai On New Political Pole, TVK & Why We The Leaders Has No Party Timeline
